Nabriva Therapeutics  has completed the acquisition of Zavante Therapeutics for $97.5m.

The acquisition will add the target company’s CONTEPO drug, which is indicated for the treatment of complicated urinary tract infections (cUTIs), to Nabriva’s late-stage anti-infective portfolio.

Based in Ireland, Nabriva is a clinical-stage biopharmaceutical company focused on the development of novel antibiotics, while Zavante is a US-based biopharmaceutical company involved in the development of novel therapies.

The acquisition enables the acquirer company to strengthen its position in the antibiotics market in the US.

Latham & Watkins has been appointed as legal adviser to Zavante Therapeutics for the transaction.

Sangamo Therapeutics has signed an agreement to acquire TxCell for €72m ($83.71m).

Sangamo will file a cash tender offer to acquire all outstanding shares of TxCell, priced at €2.58 ($2.9) a share.

“Sangamo Therapeutics has signed an agreement to acquire TxCell SA for €72m ($83.71m).”

The transaction is expected to be closed in the last quarter of 2018, subject to customary closing conditions.

Based in the US, Sangamo Therapeutics is a clinical-stage product development company, while TxCell is a cellular immunotherapy platforms developer based in France.

The transaction will enable the acquirer company to use the target company’s CAR-Treg platform and pipeline for the treatment of autoimmune diseases such as Crohn’s disease and multiple sclerosis.

Ryboquin has completed the acquisition of Nanogenic Solutions .

The target company will be named Nanogenics Limited, following the acquisition.

Ryboquin is funding the acquisition through €4.45m ($5.17m) raised in a third financing round participated by new and existing investors.

Based in the UK, Ryboquin is a pharmaceutical company that develops oncology therapies, while Nanogenic Solutions, also based in the UK, is a developer of LipTide, an artificial virus that acts as a vector for gene therapy.

The transaction is expected to enable the acquirer company to revolutionise gene therapy.